Alumis Inc. (ALMS)
NASDAQ:ALMS
Want to see ALMS full AI Analyst Report?
ALMS Stock Chart & Stats
$24.99
-$0.47(-5.84%)
At close: 4:00 PM EST
$24.99
-$0.47(-5.84%)
Day’s Range― - ―
52-Week Range$2.76 - $30.60
Previous CloseN/A
Volume29.29K
Average Volume (3M)1.59M
Market Cap
$2.98B
Enterprise Value$2.82B
Total Cash (Recent Filing)$522.94M
Total Debt (Recent Filing)$35.66M
Price to Earnings (P/E)―
Beta-1.36
Next Earnings
Aug 19, 2026EPS Estimate
-0.72Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.91
Shares Outstanding123,432,076
10 Day Avg. Volume2,295,855
30 Day Avg. Volume1,592,686
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)27.54
Price to Sales (P/S)345.07
P/FCF Ratio-22.42
Enterprise Value/Market Cap0.94
Enterprise Value/Revenue335.26
Enterprise Value/Gross Profit374.04
Enterprise Value/Ebitda-6.80
Forecast
1Y Price Target
$40.67Price Target Upside62.73% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-2.86
Revenue Forecast (FY)$7.82M
Bulls Say, Bears Say
Bulls Say
Phase 3 Efficacy And Planned U.S. FilingRobust Phase 3 efficacy with high PASI 90/100 rates materially increases the likelihood of regulatory approval and, if approved, durable market entry. A planned 2026 U.S. filing signals a clear development path from clinical-stage to potential commercial revenue and strategic positioning.
Low Financial LeverageVery low leverage provides financial flexibility to fund remaining development, absorb near-term R&D spending, and delay dilutive financing. This balance-sheet strength reduces immediate refinancing risk and supports executing the regulatory and clinical roadmap over the coming months.
High Gross Margins Indicate Favorable Unit EconomicsStrong product-level gross margins for a small-molecule therapy imply attractive unit economics if commercialization succeeds. Durable manufacturing and pricing advantages would support long-term margin sustainability once fixed R&D investment tapers and scale benefits are realized.
Bears Say
Substantial Cash Burn And Negative Operating Cash FlowVery large negative operating and free cash flow create sustained financing needs and heighten dilution risk. Persistent cash burn can force equity raises or debt access, eroding shareholder value and limiting the company's ability to self-fund late-stage filings and commercial launch preparations without external capital.
Sharp Revenue Decline And Very Small Revenue BaseA tiny and rapidly declining revenue base leaves the firm heavily reliant on R&D milestones and financing rather than operating cash. Limited recurring revenue reduces resilience to setbacks and increases the company's exposure to development delays or regulatory hurdles over the medium term.
Deep Negative Profitability And Risk To EquitySustained large operating losses translate into negative returns that can erode equity value over time. Without durable improvement in profitability or successful commercialization, continued losses increase the probability of value-dilutive financings and long-term weakening of the firm's capital base.
Alumis Inc. News
ALMS FAQ
What was Alumis Inc.’s price range in the past 12 months?
Alumis Inc. lowest stock price was $2.76 and its highest was $30.60 in the past 12 months.
What is Alumis Inc.’s market cap?
Alumis Inc.’s market cap is $2.98B.
When is Alumis Inc.’s upcoming earnings report date?
Alumis Inc.’s upcoming earnings report date is Aug 19, 2026 which is in 58 days.
How were Alumis Inc.’s earnings last quarter?
Alumis Inc. released its earnings results on May 14, 2026. The company reported -$0.74 earnings per share for the quarter, beating the consensus estimate of -$0.743 by $0.003.
Is Alumis Inc. overvalued?
According to Wall Street analysts Alumis Inc.’s price is currently Undervalued.
Does Alumis Inc. pay dividends?
Alumis Inc. does not currently pay dividends.
What is Alumis Inc.’s EPS estimate?
Alumis Inc.’s EPS estimate is -0.72.
How many shares outstanding does Alumis Inc. have?
Alumis Inc. has 123,432,076 shares outstanding.
What happened to Alumis Inc.’s price movement after its last earnings report?
Alumis Inc. reported an EPS of -$0.74 in its last earnings report, beating expectations of -$0.743. Following the earnings report the stock price went down -7.146%.
Which hedge fund is a major shareholder of Alumis Inc.?
Currently, no hedge funds are holding shares in ALMS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Alumis Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$40.67 (62.73% Upside)
$40.67 (62.73% Upside)
Hedge Fund Trend
Increased
By 294.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 0.8%
Last 30 Days ▲ 0.5%
Last 30 Days ▲ 0.5%
Technicals
SMA
Positive
20 days / 200 days
Momentum
137.50%
12-Months-Change
Fundamentals
Return on Equity
-54.63%
Trailing 12-Months
Asset Growth
157.02%
Trailing 12-Months
Company Description
Alumis Inc.
Alumis Inc. is a biopharmaceutical firm currently in the clinical trial phase, dedicated to advancing and marketing therapeutic solutions for a range of autoimmune conditions. Its pipeline includes ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor, which is being investigated for its potential in addressing plaque psoriasis, systemic lupus erythematosus, and non-infectious uveitis. Another key candidate is A-005, also an allosteric TYK2 inhibitor, specifically designed to penetrate the central nervous system to target neuroinflammatory and neurodegenerative disorders. Originally established as Esker Therapeutics, Inc., the organization rebranded as Alumis Inc. in January 2022. Founded in 2021, Alumis maintains its corporate headquarters in South San Francisco, California.
ALMS Stock 12 Month Forecast
Average Price Target
$40.67
▲(62.73% Upside)
Technical Analysis
Ownership Overview
56.33% Insiders
5.30% Mutual Funds
3.31% Other Institutional Investors
26.92% Public Companies and
Individual Investors